Related references
Note: Only part of the references are listed.Tuberculosis in biologic users for rheumatic diseases: results from the South African Biologics Registry (SABIO)
Clive Pettipher et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases
Teresa Chiacchio et al.
JOURNAL OF INFECTION (2019)
Lymphocyte subset analysis in QuantiFERON-TB Gold Plus and T-Spot.TB for latent tuberculosis infection in rheumatoid arthritis
Hidetoshi Igari et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2018)
The global burden of tuberculosis: results from the Global Burden of Disease Study 2015'
Christopher J. L. Murray et al.
LANCET INFECTIOUS DISEASES (2018)
Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease
Jieun Kang et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2018)
A Propensity-score-based Fine Stratification Approach for Confounding Adjustment When Exposure Is Infrequent
Rishi J. Desai et al.
EPIDEMIOLOGY (2017)
Tuberculosis Elimination in the United States - The Need for Renewed Action
Ronald Bayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis
Sofia Ramiro et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Efficacy of Treatment for Latent Tuberculosis in Patients Undergoing Treatment with a Tumor Necrosis Factor Antagonist
Jungsil Lee et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2017)
Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
K. L. Winthrop et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Effect of immunosuppressive therapy on interferon gamma release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis
Sunny H. Wong et al.
THORAX (2016)
Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults Evidence Report and Systematic Review for the US Preventive Services Task Force
Leila C. Kahwati et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Tuberculosis
Madhukar Pai et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice
Fabrizio Cantini et al.
AUTOIMMUNITY REVIEWS (2015)
The Risk of Tuberculosis in Korean Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Blockers
Ja Min Byun et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2015)
Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents
Eun Soo Kim et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Belimumab for Systemic Lupus Erythematosus: A Cochrane Systematic Review and MetaAnalysis
Jasvinder A. Singh et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) Study
John W. Baddley et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register
James B. Galloway et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Prophylaxis for Latent Tuberculosis Infection Prior to Anti-Tumor Necrosis Factor Therapy in Low-Risk Elderly Patients With Rheumatoid Arthritis: A Decision Analysis
Glen S. Hazlewood et al.
ARTHRITIS CARE & RESEARCH (2013)
Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis
Elizabeth C. Hsia et al.
ARTHRITIS AND RHEUMATISM (2012)
Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?
A. Strangfeld et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
New Regimens to Prevent Tuberculosis in Adults with HIV Infection
Neil A. Martinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Validation of rheumatoid arthritis diagnoses in health care utilization data
Seo Young Kim et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Treatment of latent tuberculosis infection: An update
Philip Lobue et al.
RESPIROLOGY (2010)
Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research
Peter C. Austin
COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION (2009)
Serious infection following anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis -: Lessons from interpreting data from observational studies
W. G. Dixon et al.
ARTHRITIS AND RHEUMATISM (2007)
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists
Jeffrey R. Curtis et al.
ARTHRITIS AND RHEUMATISM (2007)
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden
J Askling et al.
ARTHRITIS AND RHEUMATISM (2005)
Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists
L Carmona et al.
ARTHRITIS AND RHEUMATISM (2005)
New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality
V Sundararajan et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2004)
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk -: A multicenter active-surveillance report
JJ Gómez-Reino et al.
ARTHRITIS AND RHEUMATISM (2003)
Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management
MA Gardam et al.
LANCET INFECTIOUS DISEASES (2003)
Frequency of infection in patients with rheumatoid arthritis compared with controls - A population-based study
MF Doran et al.
ARTHRITIS AND RHEUMATISM (2002)
Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent
J Keane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
